Study Group: Ferrlecit Prescribers(?)
Council Members in this Study Group: 33
Request a survey with this Study Group
Leading Experts in this Study Group
Steven Fishbane, MD
Chief of Nephrology, Medical Director
Winthrop-University Hospital Inc
Steven Fishbane, MD, is Professor of Medicine at the State University of New York at Stony Brook School of Medicine. Additionally, Dr. Fishbane serves as Chief of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease Research at Winthrop-University Hospital...
Richard Amerling, MDDirector of Outpatient Dialysis
BETH ISRAEL MEDICAL CENTER INC
Richard Amerling, MD, is Director of Outpatient Dialysis and Continuous Renal Replacement Therapy at Beth Israel Medical Center in New York City. Dr. Amerling has an extensive background in all aspects of consultative nephrology, including hypertension, kidney stones, glomerular diseases, diabetes,...
Medical Director
Davita Los Angeles Dialysis Center
Jack Rubin, MD, is Medical Director of the Los Angeles Vascular Access Center (LAVAC) in Inglewood, California. LAVAC does out patient procedures to correct problems with vascular accesses in dialysis patients. LAVAC also does out-patient angiograms of the legs and repairs stenoses of femoral arteries...
Medical Director
Dva Renal Healthcare, Inc.
Edward Littman, MD, is the Medical Director of the Davita Dialysis Clinics in Norwalk, Connecticut. He also serves as a Clinical Associate Professor of Medicine at the Yale University School of Medicine. Dr. Littman’s major area of expertise is in dialysis treatment of chronic kidney disease. He was...
Professor
TUFTS UNIVERSITY
Michael Germain, MD, is Professor of Medicine at Tufts University in Boston. He is also an attending physician at Baystate Medical. His research interests and publications are in renal palliative care, exercise in renal patients, and predictive value of GFR measurements in renal transplant patients....
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
This article addresses government policy, taxation, insurance, and socialization implications on future patient access to physician care.
Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.
It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up. The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event.
With the pipeline for new drugs running dry, it is no surprise that pharmaceutical companies are looking to expand indications for existing products still under patent protection. What better way to do this than by creating entirely new patient populations out of whole cloth?
While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Other Freestanding Healthcare Facility
- Government/Military Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Medical Director
- Owner
- Chief Executive Officer
- President
- Director
- Research Scientist
- Physician - Department Chair
- Professor